JP7186400B2 - ゲノム的に再コードした生物におけるセレノ－生物製剤の製造 - Google Patents

ゲノム的に再コードした生物におけるセレノ－生物製剤の製造 Download PDF

Info

Publication number
JP7186400B2
JP7186400B2 JP2019531589A JP2019531589A JP7186400B2 JP 7186400 B2 JP7186400 B2 JP 7186400B2 JP 2019531589 A JP2019531589 A JP 2019531589A JP 2019531589 A JP2019531589 A JP 2019531589A JP 7186400 B2 JP7186400 B2 JP 7186400B2
Authority
JP
Japan
Prior art keywords
protein
item
sequence
selenocysteine
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019531589A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502104A5 (cg-RX-API-DMAC7.html
JP2020502104A (ja
Inventor
ダニエル ジェイ． マンデル，
ロス タイヤー，
アンドリュー ディー． エリントン，
ピーター ベンジャミン ストレンジズ，
クリストファー ジェイ． グレッグ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2020502104A publication Critical patent/JP2020502104A/ja
Publication of JP2020502104A5 publication Critical patent/JP2020502104A5/ja
Priority to JP2022184852A priority Critical patent/JP7378106B2/ja
Application granted granted Critical
Publication of JP7186400B2 publication Critical patent/JP7186400B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2019531589A 2016-08-30 2017-08-30 ゲノム的に再コードした生物におけるセレノ－生物製剤の製造 Active JP7186400B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022184852A JP7378106B2 (ja) 2016-08-30 2022-11-18 ゲノム的に再コードした生物におけるセレノ－生物製剤の製造

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662381316P 2016-08-30 2016-08-30
US62/381,316 2016-08-30
US201762537986P 2017-07-28 2017-07-28
US62/537,986 2017-07-28
PCT/US2017/049354 WO2018045018A1 (en) 2016-08-30 2017-08-30 Production of seleno-biologics in genomically recoded organisms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022184852A Division JP7378106B2 (ja) 2016-08-30 2022-11-18 ゲノム的に再コードした生物におけるセレノ－生物製剤の製造

Publications (3)

Publication Number Publication Date
JP2020502104A JP2020502104A (ja) 2020-01-23
JP2020502104A5 JP2020502104A5 (cg-RX-API-DMAC7.html) 2020-10-08
JP7186400B2 true JP7186400B2 (ja) 2022-12-09

Family

ID=61301655

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019531589A Active JP7186400B2 (ja) 2016-08-30 2017-08-30 ゲノム的に再コードした生物におけるセレノ－生物製剤の製造
JP2022184852A Active JP7378106B2 (ja) 2016-08-30 2022-11-18 ゲノム的に再コードした生物におけるセレノ－生物製剤の製造

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022184852A Active JP7378106B2 (ja) 2016-08-30 2022-11-18 ゲノム的に再コードした生物におけるセレノ－生物製剤の製造

Country Status (5)

Country Link
US (1) US11492650B2 (cg-RX-API-DMAC7.html)
EP (1) EP3506945A4 (cg-RX-API-DMAC7.html)
JP (2) JP7186400B2 (cg-RX-API-DMAC7.html)
CN (1) CN109803679A (cg-RX-API-DMAC7.html)
WO (1) WO2018045018A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP7088454B2 (ja) 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
CN109844105A (zh) 2016-07-11 2019-06-04 得克萨斯州大学系统董事会 包含硒代半胱氨酸的重组多肽及其产生方法
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
CA3106157A1 (en) * 2018-07-09 2020-01-16 Gro Biosciences Inc. Non-standard amino acid containing compositions and uses thereof
US20220144915A1 (en) * 2019-04-19 2022-05-12 The Trustees Of Indiana University Stabilization of prandial or basal insulin analogues by an internal diselenide bridge
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
IL293450A (en) 2019-12-03 2022-07-01 Evotec Int Gmbh Interferon-associated antigen binding proteins and uses thereof
JP7735291B2 (ja) 2020-02-21 2025-09-08 エーアールエス ファーマシューティカルズ、インコーポレイテッド ネクチン－４抗体コンジュゲートおよびその使用
CN113512116B (zh) * 2020-04-10 2022-09-20 苏州普乐康医药科技有限公司 一种抗igf-1r抗体及其应用
CN119792512A (zh) 2020-10-14 2025-04-11 维里迪安治疗公司 用于治疗甲状腺眼病的组合物和方法
US20230084477A1 (en) 2021-08-10 2023-03-16 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
WO2023051680A1 (zh) * 2021-09-30 2023-04-06 正大天晴药业集团股份有限公司 针对免疫检查点的双特异性抗体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011504187A (ja) 2007-11-20 2011-02-03 アンブルックス，インコーポレイテッド 修飾されたインスリンポリペプチドおよびそれらの使用
WO2013009868A1 (en) 2011-07-11 2013-01-17 Yale University Compositions and methods for making selenocysteine containing polypeptides

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849417B1 (en) * 1998-04-06 2005-02-01 The United States Of America As Represented By The Department Of Health And Human Services Mammalian selenoprotein differentially expressed in tumor cells
WO2001012657A2 (en) 1999-08-16 2001-02-22 Karolinska Innovations Ab Methods and means for selenoprotein expression
WO2007075438A2 (en) 2005-12-15 2007-07-05 Codon Devices, Inc. Polypeptides comprising unnatural amino acids, methods for their production and uses therefor
US20090155255A1 (en) * 2007-09-27 2009-06-18 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
AU2012216723B2 (en) * 2007-11-20 2014-08-28 Ambrx, Inc. Modified insulin polypeptides and their uses
JP5572972B2 (ja) * 2009-03-16 2014-08-20 Ｊｎｃ株式会社 インスリン分泌促進剤などの薬物のスクリーニング方法
WO2012031327A1 (en) * 2010-09-08 2012-03-15 Howard Florey Institute Of Experimental Physiology And Medicine Modified relaxin polypeptides
ES2746559T3 (es) * 2011-01-28 2020-03-06 Nat Res Council Canada Modificación genética de dominios de inmunoglobulina
EP3527218A1 (en) 2011-06-10 2019-08-21 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
US10240158B2 (en) 2011-07-11 2019-03-26 Yale University Compositions and methods for making selenocysteine containing polypeptides
US10876142B2 (en) 2011-07-11 2020-12-29 Yale University Compositions and methods for making selenocysteine containing polypeptides
PT2968552T (pt) 2013-03-14 2020-05-18 Scripps Research Inst Anticorpo dos agentes alvo, combinações e uso para os mesmos
US20150050682A1 (en) 2013-08-15 2015-02-19 University Of Vermont And State Agricultural College Direct assay of thioredoxin reductase activity
WO2015066543A1 (en) * 2013-11-01 2015-05-07 Board Of Regents, The University Of Texas System Targeting her2 and her3 with bispecific antibodies in cancerous cells
US10118950B2 (en) 2014-08-30 2018-11-06 Northwestern University Platforms for cell-free protein synthesis comprising extracts from genomically recoded E. coli strains having genetic knock-out mutations in release factor 1 (RF-1) and endA
WO2016172269A2 (en) * 2015-04-20 2016-10-27 University Of Utah Research Foundation Insulin analogs having shortened b chain peptides and associated methods
CN105111304B (zh) * 2015-09-30 2018-12-14 山东阿华生物药业有限公司 重组人胰岛素前体的纯化和酶切转换方法
US10557160B2 (en) 2015-12-15 2020-02-11 Board Of Regents, The University Of Texas System Transgenic bacteria with expanded amino acid usage and nucleic acid molecules for use in the same
WO2018014091A1 (en) 2016-07-22 2018-01-25 University Of Utah Research Foundation Insulin analogs
CN109844105A (zh) 2016-07-11 2019-06-04 得克萨斯州大学系统董事会 包含硒代半胱氨酸的重组多肽及其产生方法
CR20190096A (es) * 2016-07-22 2019-09-16 Walter & Eliza Hall Inst Medical Res Análogos de insulina
US20220144915A1 (en) 2019-04-19 2022-05-12 The Trustees Of Indiana University Stabilization of prandial or basal insulin analogues by an internal diselenide bridge

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011504187A (ja) 2007-11-20 2011-02-03 アンブルックス，インコーポレイテッド 修飾されたインスリンポリペプチドおよびそれらの使用
WO2013009868A1 (en) 2011-07-11 2013-01-17 Yale University Compositions and methods for making selenocysteine containing polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
52nd Japanese Peptide Symposium 第５２回ペプチド討論会 講演要旨集，2015年，Vol.52，P.78, No.P-021

Also Published As

Publication number Publication date
JP7378106B2 (ja) 2023-11-13
JP2023015347A (ja) 2023-01-31
US20190194713A1 (en) 2019-06-27
CA3034701A1 (en) 2018-03-08
EP3506945A4 (en) 2020-07-15
WO2018045018A1 (en) 2018-03-08
WO2018045018A8 (en) 2018-05-11
EP3506945A1 (en) 2019-07-10
CN109803679A (zh) 2019-05-24
US11492650B2 (en) 2022-11-08
JP2020502104A (ja) 2020-01-23

Similar Documents

Publication Publication Date Title
JP7378106B2 (ja) ゲノム的に再コードした生物におけるセレノ－生物製剤の製造
US20220213500A1 (en) Expression Process
Peternel et al. Engineering inclusion bodies for non denaturing extraction of functional proteins
JP7598243B2 (ja) 抗体発現を最適化するための方法
AU2002217505B2 (en) Process for producing recombinant protein and fused protein
CN103168046A (zh) 用于加工包涵体的方法
Vyas et al. Clinical manufacturing of recombinant human interleukin 15. I. Production cell line development and protein expression in E. coli with stop codon optimization
AU2004234282B2 (en) Chaperonine-target protein complex, method of producing the same, method of stabilizing target protein, method of immobilizing target protein, method of analyzing the structure of target protein, sustained-release preparation and method of producing antibody against target protein
de Araujo et al. Strategies for over-expression and purification of recombinant full length STAT5B in Escherichia coli
CA3034701C (en) Production of seleno-biologics in genomically recoded organisms
Yurkova et al. Production of a toxic polypeptide as a fusion inside GroEL cavity
HK40007802A (en) Production of seleno-biologics in genomically recoded organisms
JP2004081199A (ja) 組換え抗体の製造方法
JP5733693B2 (ja) 組換え型ポリペプチドの製造方法
Shayfutdinov et al. Optimization of RNA Structure Leads to Increased Biosynthesis of E. coli L-asparaginase when its Gene is Overexpressed
KR20250167672A (ko) 단일 사슬 항체 및 그 체외 합성 시스템과 용도
Galiardi Split Intein Applications for Downstream Purification and Protein Conjugation
Bartlow Design of Escherichia coli host strains for improved recombinant protein purification: An approach that bridges the upstream and downstream realms of bioprocessing

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210903

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20211008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220707

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221021

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221118

R150 Certificate of patent or registration of utility model

Ref document number: 7186400

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250